Right Biceps Pseudo-Tumor from COVID-19 Vaccination

Overview

Journal Vaccines (Basel)

Date 2024 Feb 24

PMID 38400143

Authors

Anas M Abbas

Martha L Caicedo

Timothy A Damron

Affiliations

Soon will be listed here.

Abstract

Delayed hypersensitivity reactions (DHRs) have been reported in association with COVID-19 vaccines, particularly those that are mRNA-based. Classic DHRs result in induration, erythema, tenderness, and urticaria. However, soft tissue mass is an uncommon complication of a COVID-19 vaccination-associated DHR and is rarely reported in the literature. We present a case of a 49-year-old male who recognized a mildly painful, firm soft tissue mass within the biceps mimicking neoplasm six months after receiving the booster dose of the Moderna vaccine. Non-operative conservative treatment modalities, including heating pads, ice packs, acetaminophen, and ibuprofen, failed to improve the patient's mass. The mass, which proved histologically to be an inflammatory pseudo-tumor, did not recur after complete excision. While there have been many reported cases of DHRs following COVID-19 vaccinations, we present this case to raise awareness of the development of pseudo-tumors as a possible, yet rare, clinical manifestation of DHRs following vaccination.

Citing Articles

Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era.

Iliadis A, Koletsa T, Vounotrypidis P, Fassas A, Apostolidis A, Apostolidis S Cureus. 2024; 16(11):e73121.

PMID: 39651014 PMC: 11622730. DOI: 10.7759/cureus.73121.

References

Pitlick M, Joshi A, Gonzalez-Estrada A, Chiarella S . Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy Asthma Proc. 2022; 43(1):40-43. PMC: 8749242. DOI: 10.2500/aap.2022.43.210101. View

Bae E, Bae S, Vaysblat M, Abdelwahed M, Sarkar K, Bae S . Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine. Cureus. 2023; 15(4):e37612. PMC: 10184721. DOI: 10.7759/cureus.37612. View

Hurst M, Jordan A, Capstick J, Brewerton M, Cockroft R, Ingram J . Patients with previous immediate hypersensitivity reactions to polyethylene glycol can safely receive the BNT162b2 mRNA COVID-19 vaccine. Intern Med J. 2022; 52(10):1818-1820. PMC: 9539122. DOI: 10.1111/imj.15821. View

Brockow K, Mathes S, Fischer J, Volc S, Darsow U, Eberlein B . Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis. Allergy. 2021; 77(7):2200-2210. PMC: 9011687. DOI: 10.1111/all.15183. View

Johnston M, Galan A, Watsky K, Little A . Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol. 2021; 157(6):716-720. PMC: 8117061. DOI: 10.1001/jamadermatol.2021.1214. View

Haramati N, Lorans R, Lutwin M, Kaleya R . Injection granulomas. Intramuscle or intrafat?. Arch Fam Med. 1994; 3(2):146-8. DOI: 10.1001/archfami.3.2.146. View

Guerrini G, Gioria S, Sauer A, Lucchesi S, Montagnani F, Pastore G . Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration. Int J Mol Sci. 2022; 23(16). PMC: 9408675. DOI: 10.3390/ijms23168838. View

Cook I . Best vaccination practice and medically attended injection site events following deltoid intramuscular injection. Hum Vaccin Immunother. 2015; 11(5):1184-91. PMC: 4514326. DOI: 10.1080/21645515.2015.1017694. View

Chowdhry M, Rozen W, Griffiths M . Lymphatic mapping and preoperative imaging in the management of post-mastectomy lymphoedema. Gland Surg. 2016; 5(2):187-96. PMC: 4791360. DOI: 10.3978/j.issn.2227-684X.2015.11.06. View

10.

Nakajima Y, Mukai K, Takaoka K, Hirose T, Morishita K, Yamamoto T . Establishing a new appropriate intramuscular injection site in the deltoid muscle. Hum Vaccin Immunother. 2017; 13(9):2123-2129. PMC: 5612213. DOI: 10.1080/21645515.2017.1334747. View

11.

Blumenthal K, Greenhawt M, Phillips E, Agmon-Levin N, Golden D, Shaker M . An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding. J Allergy Clin Immunol Pract. 2023; 11(11):3305-3318. DOI: 10.1016/j.jaip.2023.06.057. View

12.

Abbas A, Damron T . Shoulder Pseudo-Tumor from COVID-19 Vaccine. Vaccines (Basel). 2023; 11(4). PMC: 10145291. DOI: 10.3390/vaccines11040793. View

13.

Robinson L, Fu X, Hashimoto D, Wickner P, Shenoy E, Landman A . Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatol. 2021; 157(8):1000-1002. PMC: 8223130. DOI: 10.1001/jamadermatol.2021.2114. View

14.

Kelliher M, Levy J, Nerenz R, Poore B, Johnston A, Rogers A . Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. Arch Pathol Lab Med. 2022; 146(6):677-685. DOI: 10.5858/arpa.2021-0607-SA. View

15.

Mackenzie L, Bushell M, Newman P, Bousie J . Shoulder injury related to vaccine administration (SIRVA): What do we know about its incidence and impact?. Explor Res Clin Soc Pharm. 2022; 8:100183. PMC: 9576975. DOI: 10.1016/j.rcsop.2022.100183. View

16.

Quintero D, Patel N, Harris G, Maristany A, Alani A, Rosenberg A . COVID-19 vaccine-associated ganulomatous mass mimicking a sarcoma: a case report. Radiol Case Rep. 2022; 17(8):2775-2778. PMC: 9165447. DOI: 10.1016/j.radcr.2022.05.035. View

17.

De Sousa L, McGrail D, Li K, Marques-Piubelli M, Gonzalez C, Dai H . Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 2022; 10(3). PMC: 8896046. DOI: 10.1136/jitc-2021-004371. View

18.

Nakashima C, Kato M, Otsuka A . Cutaneous manifestations of COVID-19 and COVID-19 vaccination. J Dermatol. 2023; 50(3):280-289. DOI: 10.1111/1346-8138.16651. View

19.

Povsic T, Lawrence M, Lincoff A, Mehran R, Rusconi C, Zelenkofske S . Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol. 2016; 138(6):1712-1715. DOI: 10.1016/j.jaci.2016.04.058. View

20.

Moghimi S . Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021; 29(3):898-900. PMC: 7862013. DOI: 10.1016/j.ymthe.2021.01.030. View